Clinical trialPhase 2Completed
BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
- Outcome
- Results posted; single-arm, no comparison
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- August 2014
- Ended
- 16 March 2022
- Enrollment
- 50 participants
- Sites
- 2
- Primary outcomes
- Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone.
- Sponsor type
- Academic / other
- Results posted
- 13 August 2021
- Last update
- 1 August 2022
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 1 August 2022
- Primary outcome
- Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone.Progression- free survival: FOLFOXA: 5 (3 to 7), n = 48Overall survival: FOLFOXA: 11 (8 to 14), n = 48Values: median months, 95% Confidence IntervalTime frame: Every 3 months for up to 5 yearsNo analysis posted for this outcome (outcome 1)
- Participants
- FOLFOXA: 50 started, 48 completed
- Serious adverse events
- FOLFOXA: 10 of 48Participants with at least one serious adverse event, of those at risk, as posted
- Reported in
- The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUO… DOI 10.1097/coc.0000000000000928↗ Linked as this trial’s results paper. The numbers above are the registry’s, not the paper’s.
1 secondary outcome
- Response of Patients With Metastatic Pancreatic Cancer Who Receive the FOLFOX-A Regimen
- Complete response: FOLFOXA 2/48 [Participants] (first of 4 rows)
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
A standard treatment for your cancer is called FOLFIRINOX (this utilizes the FDA approved chemotherapy drugs fluorouracil, leucovorin, oxaliplatin and irinotecan). In this study you will receive the chemotherapy treatment FOLFOX-A (fluorouracil, oxaliplatin, leucovorin and Abraxane ®) which substitutes irinotecan for the FDA approved chemotherapy drug Abraxane ®. Even though Abraxane is FDA approved for pancreatic cancer, the combination of Abraxane with the other 3 drugs is being investigated. Your doctors are studying the activity and side effects of FOLFOX-A in advanced (metastatic) pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
See summary above
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. [Every 3 months for up to 5 years]. Median, months (95% Confidence Interval). Progression- free survival: FOLFOXA (n=48): 5 (3 to 7). Overall survival: FOLFOXA (n=48): 11 (8 to 14).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Response of Patients With Metastatic Pancreatic Cancer Who Receive the FOLFOX-A Regimen [Every 3 months for up to 5 years.]. Count Of Participants, Participants. Complete response: FOLFOXA (n=48): 2. Partial response: FOLFOXA (n=48): 12. Stable disease: FOLFOXA (n=48): 12. Progressive disease: FOLFOXA (n=48): 22.
Papers 1
- Registry-listed results paperThe Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advan… DOI 10.1097/coc.0000000000000928↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.